机构：[1]Pain Medicine, Xuanwu Hospital, Capital Medical University, Beijing, China.疼痛科首都医科大学宣武医院[2]Psychological Counselling Department, Tianjin Hospital, Tianjin, China.[3]Pain Medicine and Psychology, Xuanwu Hospital, Capital Medical University, Beijing, China.疼痛科首都医科大学宣武医院[4]Systematic Review Solutions Ltd, The Ingenuity Centre, The University of Nottingham, Nottingham, UK
This is a protocol for a Cochrane Review (Intervention). The objectives are as follows: To systematically assess the clinical effects and safety of olanzapine compared with placebo for people with schizophrenia. ? 2019 The Cochrane Collaboration.
语种：
外文
中科院(CAS)分区：
出版当年[2018]版：
大类|2 区医学
小类|2 区医学：内科
最新[2023]版：
大类|2 区医学
小类|2 区医学：内科
第一作者：
第一作者机构：[1]Pain Medicine, Xuanwu Hospital, Capital Medical University, Beijing, China.[*1]Pain Medicine, Xuanwu Hospital, Capital Medical University, No. 45 Changchun Street, XiCheng District, Beijing, China
通讯作者：
通讯机构：[*1]Pain Medicine, Xuanwu Hospital, Capital Medical University, No. 45 Changchun Street, XiCheng District, Beijing, China
推荐引用方式(GB/T 7714)：
Yan Li,Changjun Du,Ni Jiaxiang,et al.Olanzapine versus placebo for people with schizophrenia[J].Cochrane Database of Systematic Reviews.2019,2019(4):doi:10.1002/14651858.CD013310.
APA：
Yan Li,Changjun Du,Ni Jiaxiang,Yang Liqiang&Fang Qi.(2019).Olanzapine versus placebo for people with schizophrenia.Cochrane Database of Systematic Reviews,2019,(4)
MLA：
Yan Li,et al."Olanzapine versus placebo for people with schizophrenia".Cochrane Database of Systematic Reviews 2019..4(2019)
：
医学